Retraction to: Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells (Tumor Biol., (2013), 34, (1517-1522), DOI 10.1007/s13277-013-0677-3);Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells

Tumor Biology

Volumn 34, Issue 3, 2013, Pages 1517-1522

  Wang, Xinyan ^a   Liang, Yu ^a,b   Wang, Jun ^a   Wang, Min ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Shenyang Weikang Hospital   (China)

Author keywords

COX 2; CTLs; Cytotoxicity; NS 398; Ovarian carcinoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; INTERLEUKIN 2; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL DENSITY; CELL GROWTH; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL VIABILITY; CELL VOLUME; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; INCUBATION TIME; OVARY CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; RADIOIMMUNOASSAY; TUMOR ESCAPE;

EID: 84878702302     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3694-6     Document Type: Erratum

References (22)

1. Bowen NJ, Walker LD, Matyunina LV, Logani S, Totten KA, Benigno BB, et al. Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics. 2009;2:71. doi: 10.1186/1755-8794-2-71.
2. Wang X, Li L, Wang B, Xiang J. Effects of ursolic acid on the proliferation and apoptosis of human ovarian cancer cells. J Huazhong Univ Sci Technolog Med Sci. 2009;29(6):761-4. doi: 10.1007/s11596-009-0618-y.
3. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J. 1994;302(Pt 3):723-7.
4. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995;55(17):3785-9.
5. Matsubayashi H, Infante JR, Winter JM, Klein AP, Schulick R, Hruban R, et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biology & Ther. 2007;6(10):1569-75.
6. Zhu J, Zhang G, Lu H. CD24, COX-2, and p53 in epithelial ovarian cancer and its clinical significance. Front in Biosci (Elite Edition). 2012;4:2745.
7. Athanassiadou P, Grapsa D, Athanassiades P, Gonidi M, Athanassiadou AM, Tsipis A, et al. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract. 2008;204(4):241-9.
8. Park MK, Kim MK, Kim JC, Sung YK. Pattern of apoptosis by NS398, a selective COX-2 inhibitor, in hepatocellular carcinoma cell lines. Cancer Res Treat. 2005;37(5):313-7. doi: 10.4143/crt.2005.37.5.313.
9. Chang HC, Weng CF. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol Rep. 2001;8(6):1321-5.
10. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 1998;58(19):4245-9.
11. Youns M, Efferth T, Hoheisel JD. Transcript profiling identifies novel key players mediating the growth inhibitory effect of NS-398 on human pancreatic cancer cells. Eur J Pharmacol. 2011;650(1):170-7.
12. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 1998;58(6):1208-16.
13. Smyth GP, Stapleton PP, Barden CB, Mestre JR, Freeman TA, Duff MD, et al. Renal cell carcinoma induces prostaglandin E 2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells. Ann Surg Oncol. 2003;10(4):455-62.
14. Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem. 1995;270(18):10902-8.
15. Spivak B, Lamschtein C, Talmon Y, Guy N, Mester R, Feinberg I, et al. The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol. 1999;22(2):98-101.
16. Inoue H, Yokoyama C, Hara S, Tone Y, Tanabe T. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem. 1995;270(42):24965-71.
17. Kase S, Osaki M, Honjo S, Takeda A, Adachi K, Araki K, et al. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells. J Exp Clin Cancer Res. 2004;23(2):301-7.
18. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 2000;164(1):361-70.
19. Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar K, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res. 2003;9(3):961-8.
20. Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ, et al. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol. 2002;168(9):4333-43.
21. Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000;60(16):4499-506.
22. Nizamutdinova IT, Lee JH, Seo HG, Chang KC, Kim HJ. NS398 protects cells from sodium nitroprusside-mediated cytotoxicity through enhancing HO-1 induction independent of COX-2 inhibition. Arch Pharm Res. 2009;32(1):99-107. doi: 10.1007/s12272-009-1123-3.